Investors

GBT to Host Analyst & Investor Day on October 8 in New York

Press Release

View printer-friendly version
<< Back
GBT to Host Analyst & Investor Day on October 8 in New York

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ: GBT) today announced that it will host an Analyst & Investor Day to provide an update to the investment community on the company’s development and commercial strategy for voxelotor for sickle cell disease (SCD). The event will be held on Tuesday, October 8, 2019, in New York City from 9:00 a.m. to 12:00 p.m. Eastern Time.

The Analyst & Investor Day will include an overview of the SCD landscape, the significance of hemoglobin in SCD, GBT’s development program for voxelotor and the company’s plans for commercial launch. It will be hosted by members of the GBT senior management team:

 
     
  • Ted W. Love, M.D., President & Chief Executive Officer
  •  
  • David L. Johnson, Chief Commercial Officer
  •  
  • Josh Lehrer, M.D., Chief Medical Officer
  •  
  • Jonathan Sorof, M.D., Senior Vice President, Head of Medical Affairs and Program Team Leader, Voxelotor
  •  
 

In addition, the event will feature a panel of SCD advocates and physicians who will provide their expert opinions about the SCD treatment landscape. The guest panelists include:

 
     
  • Mapillar Dahn, SCD Advocate and President and Founder of MTS Sickle Cell Foundation
  •  
  • Jeremie Estepp, M.D., Medical Director, Clinical Translation Program in Hematology, St. Jude Children’s Research Hospital
  •  
  • Caterina Minniti, M.D., Professor, Clinical Medicine and Pediatrics, Albert Einstein College of Medicine and Director, Sickle Cell Center for Adults, Montefiore Medical Center
  •  
  • Shamonica Wiggins, SCD Advocate
  •  
 

The Analyst & Investor Day will be webcast live from GBT's website at www.gbt.com in the Investors section. A replay will be available for three months following the event.

About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact Information:
Stephanie Yao (investors & media)
GBT
650-741-7730
investors@gbt.com 

GBT new logo.png

Source: Global Blood Therapeutics, Inc.